Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal)
Technology appraisal
Summary (source: NICE)
Reference: TA286
Type: Technology appraisal
Published: 22 May 2013
Issued by: National Institute for Health and Care Excellence (NICE)
Full guidance: Read on nice.org.uk →
Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) is technology appraisal TA286, issued by the National Institute for Health and Care Excellence (NICE), which produces evidence-based recommendations for health and care in England.
Note: NICE guidance is published under a licence that applies to the UK and does not permit republication of the full text. This page provides the reference and a direct link to the official document. Read the full guidance on nice.org.uk →
Document official
Official summary published by the National Institute for Health and Care Excellence (nice.org.uk), last published 22 May 2013. Indicative information for healthcare professionals — refer to the full document. Reference and link only, per NICE licence.